Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has earned an average rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $25.60.

ATXS has been the subject of a number of research reports. Oppenheimer increased their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, December 10th.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Astria Therapeutics by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock worth $1,266,000 after buying an additional 8,965 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock valued at $595,000 after acquiring an additional 2,556 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Astria Therapeutics by 1,043.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company's stock worth $1,330,000 after acquiring an additional 133,379 shares during the period. Finally, Sofinnova Investments Inc. bought a new position in Astria Therapeutics in the second quarter worth $552,000. Hedge funds and other institutional investors own 98.98% of the company's stock.

Astria Therapeutics Trading Down 10.8 %

ATXS opened at $7.45 on Monday. The firm has a 50-day moving average price of $9.85 and a two-hundred day moving average price of $10.70. The stock has a market capitalization of $420.43 million, a PE ratio of -3.56 and a beta of 0.70. Astria Therapeutics has a 1-year low of $6.91 and a 1-year high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.